MEP90708A - Nova farmaceutska smješa - Google Patents

Nova farmaceutska smješa

Info

Publication number: MEP90708A
Authority: ME; Montenegro
Prior art keywords: new pharmaceutical; pharmaceutical mixture; pharmaceutically acceptable; mixture; erythropoiesis
Prior art date: 2000-05-15

Application number

MEP-907/08A

Other languages

Bosnian (bs)

English (en)

Croatian (hr)

Inventor

Apollon Papadimitriou

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-15

Filing date

2001-05-08

Publication date

2011-12-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8168722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP90708(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-05-08 Application filed filed Critical

2011-12-20 Publication of ME00673B publication Critical patent/ME00673B/me

2011-12-20 Publication of MEP90708A publication Critical patent/MEP90708A/xx

Links

239000000203 mixture Substances 0.000 title abstract 2
150000001449 anionic compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000010437 erythropoiesis Effects 0.000 abstract 1
230000000913 erythropoietic effect Effects 0.000 abstract 1
239000000945 filler Substances 0.000 abstract 1
229910001412 inorganic anion Inorganic materials 0.000 abstract 1
239000007788 liquid Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Inorganic Chemistry (AREA)
Virology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Diabetes (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Communicable Diseases (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MEP-907/08A 2000-05-15 2001-05-08 Nova farmaceutska smješa MEP90708A (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00110355		2000-05-15
PCT/EP2001/005187 WO2001087329A1 (en)	2000-05-15	2001-05-08	Liquid pharmaceutical composition containing an erythropoietin derivate

Publications (2)

Publication Number	Publication Date
ME00673B ME00673B (me)	2011-12-20
MEP90708A true MEP90708A (hr)	2011-12-20

Family

ID=8168722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-907/08A MEP90708A (hr)	2000-05-15	2001-05-08	Nova farmaceutska smješa

Country Status (35)

Country	Link
US (2)	US7169754B2 (de)
EP (2)	EP1525889A1 (de)
JP (1)	JP3967594B2 (de)
KR (3)	KR100758044B1 (de)
CN (1)	CN1309416C (de)
AR (2)	AR035034A1 (de)
AT (1)	ATE291436T2 (de)
AU (1)	AU784091B2 (de)
BR (1)	BRPI0110914B8 (de)
CA (1)	CA2408685C (de)
CZ (1)	CZ304855B6 (de)
DE (1)	DE60109625T3 (de)
DK (1)	DK1311285T4 (de)
EC (2)	ECSP024352A (de)
ES (1)	ES2237574T5 (de)
HR (1)	HRP20020880B1 (de)
HU (1)	HU230874B1 (de)
IL (2)	IL152659A0 (de)
JO (1)	JO3404B1 (de)
MA (1)	MA26901A1 (de)
ME (1)	MEP90708A (de)
MX (1)	MXPA02011303A (de)
MY (1)	MY128654A (de)
NO (1)	NO330934B1 (de)
NZ (1)	NZ522030A (de)
PE (1)	PE20020050A1 (de)
PL (1)	PL219131B1 (de)
PT (1)	PT1311285E (de)
RS (1)	RS51292B (de)
RU (1)	RU2281116C2 (de)
SI (1)	SI1311285T1 (de)
TW (2)	TWI288644B (de)
UY (1)	UY26704A1 (de)
WO (1)	WO2001087329A1 (de)
ZA (1)	ZA200208500B (de)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5545553A (en) *	1994-09-26	1996-08-13	The Rockefeller University	Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US7304150B1 (en) *	1998-10-23	2007-12-04	Amgen Inc.	Methods and compositions for the prevention and treatment of anemia
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JP2003530838A (ja) *	2000-04-12	2003-10-21	ヒューマンゲノムサイエンシズインコーポレイテッド	アルブミン融合タンパク質
ATE291436T2 (de)	2000-05-15	2005-04-15	Hoffmann La Roche	Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
MXPA03005406A (es)	2000-12-20	2003-09-25	Hoffmann La Roche	Conjugados de eritropoyetina.
EP1345628B1 (de) *	2000-12-20	2011-04-13	F. Hoffmann-La Roche AG	Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
FR2823220B1 (fr) *	2001-04-04	2003-12-12	Genodyssee	Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
CA2446739A1 (en) *	2001-05-25	2002-12-05	Human Genome Sciences, Inc.	Chemokine beta-1 fusion proteins
US20030104996A1 (en) *	2001-08-30	2003-06-05	Tiansheng Li	L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
JP2003152145A (ja) *	2001-08-31	2003-05-23	Sumitomo Electric Ind Ltd	半導体放熱用基板とその製造方法及びパッケージ
US8008252B2 (en)	2001-10-10	2011-08-30	Novo Nordisk A/S	Factor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en)	2001-10-10	2007-05-08	Neose Technologies, Inc.	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en)	2001-10-10	2007-02-06	Neose Technologies, Inc.	Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7179617B2 (en) *	2001-10-10	2007-02-20	Neose Technologies, Inc.	Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en) *	2001-10-10	2010-09-14	Novo Nordisk A/S	Protein remodeling methods and proteins/peptides produced by the methods
US7399613B2 (en) *	2001-10-10	2008-07-15	Neose Technologies, Inc.	Sialic acid nucleotide sugars
US7696163B2 (en)	2001-10-10	2010-04-13	Novo Nordisk A/S	Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7157277B2 (en)	2001-11-28	2007-01-02	Neose Technologies, Inc.	Factor VIII remodeling and glycoconjugation of Factor VIII
US7473680B2 (en)	2001-11-28	2009-01-06	Neose Technologies, Inc.	Remodeling and glycoconjugation of peptides
ES2425738T3 (es) *	2001-12-21	2013-10-17	Human Genome Sciences, Inc.	Proteínas de fusión de la albúmina
AU2002364587A1 (en) *	2001-12-21	2003-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
MXPA04012496A (es) *	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Glicoformos del factor vii pegilados.
SI21258A (sl) *	2002-07-17	2004-02-29	LEK farmacevtska dru�ba d.d.	Stabilni farmacevtski pripravek, ki vsebuje eritropoietin in poloksamerni poliol
US7459435B2 (en) *	2002-08-29	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
MXPA05002617A (es) *	2002-09-09	2005-09-08	Warren Pharmaceuticals Inc	Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.
US7470779B2 (en) *	2002-09-20	2008-12-30	Pfizer Inc.	Process for decreasing aggregate levels of pegylated protein
US7459436B2 (en)	2002-11-22	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
EP1594530A4 (de)	2003-01-22	2006-10-11	Human Genome Sciences Inc	Albuminfusionsproteine
CN102212019B (zh) *	2003-03-14	2015-05-27	蔚所番有限公司	支化水溶性聚合物及其缀合物
US8791070B2 (en)	2003-04-09	2014-07-29	Novo Nordisk A/S	Glycopegylated factor IX
WO2006127896A2 (en) *	2005-05-25	2006-11-30	Neose Technologies, Inc.	Glycopegylated factor ix
EP1615945B1 (de) *	2003-04-09	2011-09-28	BioGeneriX AG	Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
WO2004091499A2 (en) *	2003-04-09	2004-10-28	Neose Technologies, Inc.	Intracellular formation of peptide conjugates
MXPA05011832A (es) *	2003-05-09	2006-02-17	Neose Technologies Inc	Composiciones y metodos para la preparacion de mutantes de glicosilacion de la hormona de crecimiento humano.
DK1625156T3 (da) *	2003-05-12	2013-01-07	Affymax Inc	Peptider, der bindes til erythropoietinreceptoren
MXPA05012314A (es)	2003-05-12	2006-04-18	Affymax Inc	Radical separador para peptido modificado con polietilenglicol.
PT1629007E (pt) *	2003-05-12	2009-05-06	Affymax Inc	Péptidos novos que se ligam ao receptor da eritropoietina
CA2525464A1 (en) *	2003-05-12	2004-11-25	Qun Yin	Novel poly(ethylene glycol) modified compounds and uses thereof
NZ543859A (en) *	2003-06-10	2008-01-31	Lg Life Sciences Ltd	Aqueous formulation that has storage stability over a long period without serum albumin comprising human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers
WO2005012484A2 (en)	2003-07-25	2005-02-10	Neose Technologies, Inc.	Antibody-toxin conjugates
AU2004293103C1 (en) *	2003-11-24	2010-12-02	Ratiopharm Gmbh	Glycopegylated erythropoietin
US20080305992A1 (en) *	2003-11-24	2008-12-11	Neose Technologies, Inc.	Glycopegylated erythropoietin
US8633157B2 (en) *	2003-11-24	2014-01-21	Novo Nordisk A/S	Glycopegylated erythropoietin
US20060040856A1 (en)	2003-12-03	2006-02-23	Neose Technologies, Inc.	Glycopegylated factor IX
EP1694274B1 (de) *	2003-12-03	2013-04-24	BioGeneriX AG	Glykopegylierter Granulocyten-Kolonie-stimulierender Faktor
US20080318850A1 (en) *	2003-12-03	2008-12-25	Neose Technologies, Inc.	Glycopegylated Factor Ix
US7956032B2 (en)	2003-12-03	2011-06-07	Novo Nordisk A/S	Glycopegylated granulocyte colony stimulating factor
JP2007514673A (ja)	2003-12-19	2007-06-07	エフ．ホフマン−ラ　ロシュ　アーゲー	慢性炎症性腸疾患の際の鉄分布障害の処置におけるエリスロポエチンの使用
US8361961B2 (en) *	2004-01-08	2013-01-29	Biogenerix Ag	O-linked glycosylation of peptides
US8778880B2 (en) *	2004-02-02	2014-07-15	Ambrx, Inc.	Human growth hormone modified at position 35
DE202004020676U1 (de) *	2004-03-10	2005-11-10	Bioceuticals Arzneimittel Ag	Erythropoietin-Flüssigformulierung
US20050282751A1 (en) *	2004-03-19	2005-12-22	Ajinomoto Co., Inc.	Therapeutic agent for renal anemia
EP1726303A4 (de) *	2004-03-19	2011-03-02	Ajinomoto Kk	Therapeutisches mittel gegen nierenanämie
US20050267026A1 (en) *	2004-03-26	2005-12-01	Cheung Wing K	Combination dosing regimen for erythropoietin
AR049580A1 (es) *	2004-07-07	2006-08-16	Lundbeck & Co As H	Epo carbamilada y metodo para su produccion
WO2006010143A2 (en)	2004-07-13	2006-01-26	Neose Technologies, Inc.	Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006020372A2 (en) *	2004-07-23	2006-02-23	Neose Technologies, Inc.	Enzymatic modification of glycopeptides
US20060029551A1 (en) *	2004-08-05	2006-02-09	Kui Liu	Stable particle formulations of erythropoietin receptor agonists
US7772182B2 (en) *	2004-08-05	2010-08-10	Alza Corporation	Stable suspension formulations of erythropoietin receptor agonists
EP1799249A2 (de) *	2004-09-10	2007-06-27	Neose Technologies, Inc.	Glycopegyliertes interferon alpha
EP1814573B1 (de)	2004-10-29	2016-03-09	ratiopharm GmbH	Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
JP2006137678A (ja) *	2004-11-10	2006-06-01	Shionogi & Co Ltd	インターロイキン−２組成物
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
JP2008519858A (ja) *	2004-11-11	2008-06-12	アフィーマックス・インコーポレイテッド	エリスロポエチンレセプターに結合する新規ペプチド
US20100009902A1 (en) *	2005-01-06	2010-01-14	Neose Technologies, Inc.	Glycoconjugation Using Saccharyl Fragments
CA2593682C (en)	2005-01-10	2016-03-22	Neose Technologies, Inc.	Glycopegylated granulocyte colony stimulating factor
EP1844068A4 (de) *	2005-01-25	2009-09-30	Apollo Life Sciences Ltd	Moleküle und chimere moleküle davon
EP1866427A4 (de) *	2005-03-30	2010-09-01	Novo Nordisk As	Herstellungsverfahren zur produktion von in insektenzelllinien entstandenen peptiden
EP1871795A4 (de) *	2005-04-08	2010-03-31	Biogenerix Ag	Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
US20070037886A1 (en) *	2005-04-26	2007-02-15	Ajinomoto Co., Inc.	Bone marrow erythroid progenitor cell(s) differentiation inducer
US20110003744A1 (en) *	2005-05-25	2011-01-06	Novo Nordisk A/S	Glycopegylated Erythropoietin Formulations
EP1888098A2 (de) *	2005-05-25	2008-02-20	Neose Technologies, Inc.	Glykopegylierte erythropoetin-formulierungen
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) *	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
AU2006295340B2 (en)	2005-08-05	2010-11-11	Amgen Inc.	Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US20070105755A1 (en)	2005-10-26	2007-05-10	Neose Technologies, Inc.	One pot desialylation and glycopegylation of therapeutic peptides
US20090305967A1 (en) *	2005-08-19	2009-12-10	Novo Nordisk A/S	Glycopegylated factor vii and factor viia
US20070072795A1 (en) *	2005-09-28	2007-03-29	Anton Haselbeck	Treatment of neurodegenerative disorders
WO2007056191A2 (en)	2005-11-03	2007-05-18	Neose Technologies, Inc.	Nucleotide sugar purification using membranes
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
ME00380B (me)	2005-11-23	2011-10-10	Acceleron Pharma Inc	Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
CN101015684B (zh) *	2006-02-10	2011-08-24	华北制药集团新药研究开发有限责任公司	一种重组人红细胞生成素溶液制剂
WO2007108505A1 (ja) *	2006-03-22	2007-09-27	Chugai Seiyaku Kabushiki Kaisha	エリスロポエチン溶液製剤
US9187532B2 (en)	2006-07-21	2015-11-17	Novo Nordisk A/S	Glycosylation of peptides via O-linked glycosylation sequences
SI2054074T1 (sl) *	2006-08-04	2014-12-31	Prolong Pharmaceuticals Llc	Modificiran eritropoetin
US20100075375A1 (en) *	2006-10-03	2010-03-25	Novo Nordisk A/S	Methods for the purification of polypeptide conjugates
CA2665480C (en) *	2006-10-04	2019-11-12	Novo Nordisk A/S	Glycerol linked pegylated sugars and glycopeptides
WO2008073620A2 (en) *	2006-11-02	2008-06-19	Neose Technologies, Inc.	Manufacturing process for the production of polypeptides expressed in insect cell-lines
US8895016B2 (en)	2006-12-18	2014-11-25	Acceleron Pharma, Inc.	Antagonists of activin-actriia and uses for increasing red blood cell levels
TW201940502A (zh)	2007-02-02	2019-10-16	美商艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN101796063B (zh)	2007-04-03	2017-03-22	拉蒂奥法姆有限责任公司	使用糖聚乙二醇化g‑csf的治疗方法
US20090053167A1 (en) *	2007-05-14	2009-02-26	Neose Technologies, Inc.	C-, S- and N-glycosylation of peptides
US20080286341A1 (en) *	2007-05-16	2008-11-20	Sven-Borje Andersson	Buffered coated nicotine containing products
CN101778937A (zh) *	2007-06-04	2010-07-14	诺和诺德公司	使用n-乙酰葡糖胺转移酶的o-联糖基化
WO2008154639A2 (en)	2007-06-12	2008-12-18	Neose Technologies, Inc.	Improved process for the production of nucleotide sugars
WO2009002521A2 (en) *	2007-06-25	2008-12-31	Amgen Inc.	Compositions of specific binding agents to hepatocyte growth factor
US7968811B2 (en) *	2007-06-29	2011-06-28	Harley-Davidson Motor Company Group, Inc.	Integrated ignition and key switch
AR067537A1 (es) *	2007-07-17	2009-10-14	Hoffmann La Roche	Purificacion de polipeptidos pegilados
AR067536A1 (es) *	2007-07-17	2009-10-14	Hoffmann La Roche	Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
MX2010002448A (es)	2007-08-27	2010-10-04	Biogenerix Ag	Formulacion liquida del g-csf conjugado.
US8207112B2 (en) *	2007-08-29	2012-06-26	Biogenerix Ag	Liquid formulation of G-CSF conjugate
CN101456911A (zh) *	2007-12-12	2009-06-17	江苏豪森药业股份有限公司	促红细胞生成素模拟肽衍生物及其可药用盐和其制备方法与用途
WO2009089396A2 (en) *	2008-01-08	2009-07-16	Neose Technologies, Inc.	Glycoconjugation of polypeptides using oligosaccharyltransferases
CN103497247A (zh)	2008-02-27	2014-01-08	诺沃—诺迪斯克有限公司	缀合的因子viii分子
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (lt)	2008-08-14	2023-06-26	Acceleron Pharma Inc.	Gdf gaudyklės
EP2334699B1 (de) *	2008-09-23	2013-09-11	F. Hoffmann-La Roche AG	Aufreinigung von erythropoietin
MX385318B (es)	2009-06-08	2025-03-18	Acceleron Pharma Inc	Metodos para aumentar adipocitos termogenicos.
JP2012529294A (ja)	2009-06-12	2012-11-22	アクセルロンファーマ，インコーポレイテッド	切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質
SG177319A1 (en)	2009-06-24	2012-02-28	Hoffmann La Roche	Characterization of re-useable chromatography equipment
BRPI0902481B8 (pt) *	2009-07-31	2021-05-25	Soc Beneficente De Senhoras Hospital Sirio Libanes	composição farmacêutica compreendendo hemopressina e seu uso.
CA2770822C (en) *	2009-08-13	2020-03-24	Acceleron Pharma Inc.	Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
UA107678C2 (uk) *	2009-09-23	2015-02-10	ратіофарм ГмбХ	Процес очищення рекомбінантного людського еритропоетину (епо), епо, очищений таким чином, та фармацевтична композиція, що містить його
EP2501400B1 (de)	2009-11-17	2017-11-01	Acceleron Pharma, Inc.	Actriib-proteine und varianten davon sowie ihre anwendung zur utrophin-induktion für therapien gegen muskuläre dystrophie
ES2524897T3 (es)	2010-12-21	2014-12-15	F. Hoffmann-La Roche Ag	Caracterización de equipos de cromatografía
AR094821A1 (es) *	2012-07-25	2015-09-02	Hanmi Pharm Ind Co Ltd	Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
CN102816227A (zh) *	2012-08-30	2012-12-12	深圳赛保尔生物药业有限公司	回收促红细胞生成素的方法
RU2018145985A (ru)	2012-11-02	2019-02-18	Селджин Корпорейшн	Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CU20140003A7 (es)	2014-01-08	2015-08-27	Ct De Inmunología Molecular Biofarmacuba	Conjugado que comprende eritropoyetina y una estructura polimérica ramificada
US10052361B2 (en)	2014-03-29	2018-08-21	Intas Pharmaceuticals Ltd	Liquid pharmaceutical composition of conjugated erythropoietin
TN2016000553A1 (en)	2014-06-13	2018-04-04	Acceleron Pharma Inc	Methods and compositions for treating ulcers
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US11608357B2 (en)	2018-08-28	2023-03-21	Arecor Limited	Stabilized antibody protein solutions
EP3372242A1 (de)	2017-03-06	2018-09-12	Ares Trading S.A.	Flüssige pharmazeutische zusammensetzung
EP3372241A1 (de)	2017-03-06	2018-09-12	Ares Trading S.A.	Flüssige pharmazeutische zusammensetzung
WO2018184692A1 (en) *	2017-04-07	2018-10-11	Ares Trading S.A.	Liquid pharmaceutical composition
CN111727063A (zh) *	2017-12-29	2020-09-29	豪夫迈·罗氏有限公司	用于提供聚乙二醇化蛋白质组合物的方法
CN111558046A (zh) *	2020-05-27	2020-08-21	华润昂德生物药业有限公司	海藻糖在制备重组人促红素液体制剂中的应用及重组人促红素液体制剂、制备方法和应用
TWI740635B (zh) *	2020-09-09	2021-09-21	財團法人工業技術研究院	聚偏氟乙烯薄膜組成物及聚偏氟乙烯隔離膜

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US147431A (en) *		1874-02-10		Improvement in game boards
US115833A (en) *		1871-06-13		Improvement in grain-driers
JPS6197229A (ja)	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
US4732889A (en)	1985-02-06	1988-03-22	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
DE3729863A1 (de) *	1987-09-05	1989-03-16	Boehringer Mannheim Gmbh	Stabilisierte erythropoietin-lyophilisate
DE3734923C1 (de)	1987-10-15	1989-01-26	Biotest Pharma Gmbh	Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
DE4014654A1 (de)	1990-05-08	1991-11-14	Behringwerke Ag	Galenische waessrige formulierungen von erythropoietin und ihre verwendung
WO1992006116A1 (en) *	1990-09-28	1992-04-16	Ortho Pharmaceutical Corporation	Hybrid growth factors
US5272135A (en)	1991-03-01	1993-12-21	Chiron Ophthalmics, Inc.	Method for the stabilization of methionine-containing polypeptides
US6565841B1 (en)	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
NZ244778A (en)	1991-10-21	1994-03-25	Ortho Pharma Corp	Peg imidates and protein derivatives thereof
US5460944A (en)	1991-10-28	1995-10-24	Boehringer Mannheim Gmbh	Storable protein solution
DE4135542A1 (de)	1991-10-28	1993-04-29	Boehringer Mannheim Gmbh	Lagerfaehige proteinloesungen
US5716644A (en) *	1992-06-11	1998-02-10	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) *	1992-08-06	1997-08-26	Amgen, Inc.	Stable and preserved erythropoietin compositions
US5354934A (en) †	1993-02-04	1994-10-11	Amgen Inc.	Pulmonary administration of erythropoietin
AU7097094A (en)	1993-06-01	1994-12-20	Enzon, Inc.	Carbohydrate-modified polymer conjugates with erythropoietic activity
CN1057534C (zh) *	1993-08-17	2000-10-18	柯瑞英-艾格公司	促红细胞生成素类似物
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
TW518219B (en)	1996-04-26	2003-01-21	Chugai Pharmaceutical Co Ltd	Erythropoietin solution preparation
AU3908597A (en) *	1996-08-02	1998-02-25	Ortho-Mcneil Pharmaceutical, Inc.	Polypeptides having a single covalently bound n-terminal water-soluble polymer
US5919656A (en)	1996-11-15	1999-07-06	Amgen Canada Inc.	Genes encoding telomerase protein 1
EP0885613A1 (de)	1997-06-21	1998-12-23	Roche Diagnostics GmbH	Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
DE19734293A1 (de)	1997-08-08	1999-02-11	Boehringer Mannheim Gmbh	Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
PT1813624E (pt)	1998-10-23	2010-10-27	Amgen Inc	Métodos e composições para a prevenção e tratamento da anemia
UY25790A1 (es)	1998-11-06	2000-08-21	Bio Sidus S A	Formas farmaceuticas de eritropoyetina humana recombinante estables a temperatura ambiente y apropiadas para su uso en humanos, formulaciones y procedimientos de liofilizacion para su obtencion.
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
ATE401908T1 (de)	1999-04-09	2008-08-15	Ortho Mcneil Pharm Inc	Pharmazeutische zusammensetzungen von erythropoietin
US6309663B1 (en)	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
JO2291B1 (en) *	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
CZ299516B6 (cs) †	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
DE60022759T2 (de)	1999-07-22	2006-06-22	Aventis Pharmaceuticals Inc.	Erythropoietin formulierungen des mehrfachdosis-typs
ATE389414T1 (de) †	1999-09-08	2008-04-15	Chugai Pharmaceutical Co Ltd	Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
AU2001236005A1 (en)	2000-02-29	2001-09-12	Chugai Seiyaku Kabushiki Kaisha	Preparations stabilized over long time
US6586398B1 (en)	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
ATE291436T2 (de) *	2000-05-15	2005-04-15	Hoffmann La Roche	Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
WO2002011753A1 (en) †	2000-08-04	2002-02-14	Chugai Seiyaku Kabushiki Kaisha	Protein injection preparations
MXPA03005406A (es) *	2000-12-20	2003-09-25	Hoffmann La Roche	Conjugados de eritropoyetina.
US20030104996A1 (en)	2001-08-30	2003-06-05	Tiansheng Li	L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US6818613B2 (en)	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins

2001
- 2001-05-08 AT AT01943331T patent/ATE291436T2/de active
- 2001-05-08 IL IL15265901A patent/IL152659A0/xx unknown
- 2001-05-08 KR KR1020027015429A patent/KR100758044B1/ko not_active Expired - Lifetime
- 2001-05-08 KR KR1020057023568A patent/KR20050121762A/ko not_active Ceased
- 2001-05-08 PT PT01943331T patent/PT1311285E/pt unknown
- 2001-05-08 KR KR1020077003371A patent/KR20070032815A/ko not_active Ceased
- 2001-05-08 ME MEP-907/08A patent/MEP90708A/xx unknown
- 2001-05-08 MX MXPA02011303A patent/MXPA02011303A/es active IP Right Grant
- 2001-05-08 CZ CZ2002-4005A patent/CZ304855B6/cs not_active IP Right Cessation
- 2001-05-08 EP EP05000984A patent/EP1525889A1/de not_active Withdrawn
- 2001-05-08 EP EP01943331.7A patent/EP1311285B2/de not_active Expired - Lifetime
- 2001-05-08 HR HR20020880A patent/HRP20020880B1/xx not_active IP Right Cessation
- 2001-05-08 AU AU65934/01A patent/AU784091B2/en not_active Expired
- 2001-05-08 ES ES01943331.7T patent/ES2237574T5/es not_active Expired - Lifetime
- 2001-05-08 WO PCT/EP2001/005187 patent/WO2001087329A1/en not_active Ceased
- 2001-05-08 NZ NZ522030A patent/NZ522030A/en not_active IP Right Cessation
- 2001-05-08 JP JP2001583796A patent/JP3967594B2/ja not_active Expired - Lifetime
- 2001-05-08 HU HU0302114A patent/HU230874B1/hu unknown
- 2001-05-08 BR BRPI0110914A patent/BRPI0110914B8/pt not_active IP Right Cessation
- 2001-05-08 CN CNB018095607A patent/CN1309416C/zh not_active Expired - Lifetime
- 2001-05-08 DK DK01943331.7T patent/DK1311285T4/en active
- 2001-05-08 RS YUP-835/02A patent/RS51292B/sr unknown
- 2001-05-08 DE DE60109625.8T patent/DE60109625T3/de not_active Expired - Lifetime
- 2001-05-08 RU RU2002133236/15A patent/RU2281116C2/ru active
- 2001-05-08 CA CA2408685A patent/CA2408685C/en not_active Expired - Lifetime
- 2001-05-08 PL PL361341A patent/PL219131B1/pl unknown
- 2001-05-08 SI SI200130331T patent/SI1311285T1/xx unknown
- 2001-05-09 JO JOP/2001/0065A patent/JO3404B1/ar active
- 2001-05-11 US US09/853,731 patent/US7169754B2/en not_active Expired - Lifetime
- 2001-05-11 AR ARP010102248A patent/AR035034A1/es not_active Application Discontinuation
- 2001-05-11 MY MYPI20012197A patent/MY128654A/en unknown
- 2001-05-11 PE PE2001000421A patent/PE20020050A1/es active IP Right Grant
- 2001-05-14 TW TW094134688A patent/TWI288644B/zh not_active IP Right Cessation
- 2001-05-14 UY UY26704A patent/UY26704A1/es not_active IP Right Cessation
- 2001-05-14 TW TW090111453A patent/TWI288643B/zh not_active IP Right Cessation
2002
- 2002-10-21 ZA ZA200208500A patent/ZA200208500B/en unknown
- 2002-11-05 IL IL152659A patent/IL152659A/en active IP Right Grant
- 2002-11-13 MA MA26907A patent/MA26901A1/fr unknown
- 2002-11-14 NO NO20025450A patent/NO330934B1/no not_active IP Right Cessation
- 2002-11-20 EC EC2002004352A patent/ECSP024352A/es unknown
2004
- 2004-02-17 US US10/780,297 patent/US7202208B2/en not_active Expired - Lifetime
2010
- 2010-12-21 EC EC2010004352A patent/ECSP10004352A/es unknown
2013
- 2013-10-04 AR ARP130103618A patent/AR092919A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
HU230874B1 (hu)	2018-11-29
IL152659A (en)	2010-12-30
HUP0302114A2 (hu)	2003-10-28
NO330934B1 (no)	2011-08-22
PL219131B1 (pl)	2015-03-31
HRP20020880A2 (en)	2004-12-31
TWI288643B (en)	2007-10-21
BR0110914A (pt)	2003-02-11
ZA200208500B (en)	2004-01-28
EP1311285B1 (de)	2005-03-23
WO2001087329A8 (en)	2002-03-07
MA26901A1 (fr)	2004-12-20
IL152659A0 (en)	2003-06-24
US7169754B2 (en)	2007-01-30
ECSP10004352A (es)	2011-01-31
SI1311285T1 (de)	2005-08-31
CA2408685C (en)	2011-02-01
AR092919A2 (es)	2015-05-06
EP1311285B2 (de)	2017-04-12
PE20020050A1 (es)	2002-02-01
RU2281116C2 (ru)	2006-08-10
NZ522030A (en)	2004-11-26
CZ304855B6 (cs)	2014-12-10
ATE291436T2 (de)	2005-04-15
TWI288644B (en)	2007-10-21
ES2237574T5 (es)	2017-08-09
AR035034A1 (es)	2004-04-14
JP3967594B2 (ja)	2007-08-29
DE60109625D1 (de)	2005-04-28
MY128654A (en)	2007-02-28
PT1311285E (pt)	2005-06-30
JP2003533487A (ja)	2003-11-11
CZ20024005A3 (cs)	2004-01-14
DK1311285T3 (da)	2005-06-27
JO3404B1 (ar)	2019-10-20
US7202208B2 (en)	2007-04-10
CN1429116A (zh)	2003-07-09
ME00673B (me)	2011-12-20
KR20070032815A (ko)	2007-03-22
ES2237574T3 (es)	2005-08-01
CN1309416C (zh)	2007-04-11
US20040147431A1 (en)	2004-07-29
HUP0302114A3 (en)	2012-12-28
HRP20020880B1 (en)	2006-04-30
YU83502A (sh)	2005-11-28
ECSP024352A (es)	2003-03-31
RS51292B (sr)	2010-12-31
MXPA02011303A (es)	2003-04-25
AU6593401A (en)	2001-11-26
KR20050121762A (ko)	2005-12-27
BRPI0110914B1 (pt)	2016-03-01
UY26704A1 (es)	2001-12-28
PL361341A1 (pl)	2004-10-04
KR100758044B1 (ko)	2007-09-11
NO20025450D0 (no)	2002-11-14
WO2001087329A1 (en)	2001-11-22
BRPI0110914B8 (pt)	2021-05-25
DE60109625T3 (de)	2017-08-03
AU784091B2 (en)	2006-02-02
US20020037841A1 (en)	2002-03-28
DK1311285T4 (en)	2017-07-24
NO20025450L (no)	2002-11-14
EP1311285A2 (de)	2003-05-21
EP1525889A1 (de)	2005-04-27
CA2408685A1 (en)	2001-11-22
HK1056683A1 (en)	2004-02-27
KR20030001509A (ko)	2003-01-06
DE60109625T2 (de)	2006-03-30

Publication	Publication Date	Title
MEP90708A (hr)	2011-12-20	Nova farmaceutska smješa
BR0108173A (pt)	2003-01-21	Composições farmacêuticas de toxina de botulina
MEP19308A (en)	2010-06-10	Pyrrolopyrimidines as protein kinase inhibitors
BRPI0416801A (pt)	2007-01-09	derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
BR0009042A (pt)	2001-12-26	Composto, uso do mesmo, processo para prepararum composto, composição farmacêutica, e, métodospara tratar uma doença em um animal em que aatividade de cisteìna protease contribui para apatologia e/ou sintomatologia da doença, e paratratar uma doença em um animal em que a atividadede catepsina s contribui para a patologia e/ousintomatologia da doença
PT1079806E (pt)	2006-06-30	Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
CY1118991T1 (el)	2018-01-10	Φαρμακοτεχνικη μορφη ανθρωπινων αντισωματων για θεραπεια σχετικων με tnf-αλφα διαταραχων
MXPA02006679A (es)	2005-12-19	Composicion farmaceutica.
NO963499L (no)	1996-10-14	Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
IT1252868B (it)	1995-06-28	Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico
MEP25408A (en)	2010-06-10	Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same
TR199903191T2 (xx)	2000-09-21	Vorikonazol i�eren ila� form�lasyonlar�.
YU53098A (sh)	2000-03-21	Preparat koncentrovanog antitela
BRPI0108395B8 (pt)	2021-05-25	derivados de pirrolopirimidinona, processos de preparação e uso
BR0214243A (pt)	2004-12-21	Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
BR9611571A (pt)	1999-03-30	Composição farmacêutica estável composição farmacêutica kit para administração de ngf e método de aumento da estabilidade de ngf
DE50115451D1 (de)	2010-06-02	Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
PT1228097E (pt)	2006-05-31	Actividade antimicrobiana do primeiro grupo cationico da lactoferrina humana
AU2001274374A1 (en)	2002-01-02	Matrix protein compositions for dentin regeneration
BR0212249A (pt)	2004-10-05	Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
BR0108980A (pt)	2003-06-03	Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
BR0318659A (pt)	2006-11-28	derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
SE0001916D0 (sv)	2000-05-23	Novel formulation
BR0109279A (pt)	2002-12-17	Antagonistas de lhrh, sua preparação e aplicação como medicamento
MEP39708A (en)	2011-02-10	New pharmaceutical compositions containing epinastine and pseudoephedrine